The Priority Review

Tag

Telix Pharmaceuticals

1 story

Stories

  1. Clinical trials

    Telix registers Phase 3 study of [18F]FET PET in brain metastases

    The study, led by Telix Pharmaceuticals (Innovations) Pty Limited, plans to enroll 381 participants and begin in December 2026. It will evaluate whether [18F]Floretyrosine PET can differentiate tumor progression from treatment-related changes in patients with brain metastases and equivocal MRI findings.